Success in gene and cell therapy has increased the demand for high-quality plasmid DNA production. Not limited to the production of viral vectors, plasmid DNA can be served either as a delivery vehicle itself, or a template for mRNA vaccines. For different applications, the requirements for the plasmid DNA production are different.
GenScript ProBio has accumulated experience in plasmid production for lentiviral vectors, AAV vectors, mRNA vaccines, and DNA vaccines. We will share our experience in dealing with challenges in plasmid production with cases studies.
Speaker Biography:
Dr. Ming Ni received his doctoral degree from the University of Washington. He joined GenScript in January, 2020, and has been responsible for technical support of plasmid DNA platform. He led the plasmid DNA project to improve the yield and optimize purification steps. Before he joined GenScript, he was a full professor and department head of Biomedical Engineering Department at Yachay Tech University. With over 50 peer-reviewed articles, 1600 citations and 4 US patents, he is one of the most prolific scientists at GenScript.
Aavailable for packaging the 3rd generation lentiviral vector, to support pre-clinical and clinical phases’ needs.
Comprehensive quality assurance to meet your needs in early stage clinical.
Fulfills your expectation in pre-IND phases and bring your projects through non-clinical stages cost-effectively.
Highest quality standards and regulatory compliance
About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud